Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906404 | 0.89 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2 | |
| SCHEMBL14395281 | 0.83 | SLC15A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2 | |
| SCHEMBL26505618 | 0.83 | SLC15A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2 | |
| SCHEMBL3905724 | 0.82 | CNR2 (0.43) | EPHX1ALDH1A1MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3907689 | 0.82 | SMN1; SMN2 (0.43) | ALDH1A1MAPK1L3MBTL1SLC15A1SMN1; SMN2 | |
| SCHEMBL3901687 | 0.79 | CNR2 (0.44) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL1705106 | 0.78 | ALDH1A1 (0.56) | EPHX1ALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL28609652 | 0.78 | EPHX1 (0.77) | EPHX1MEN1KMT2ACNR2 | |
| SCHEMBL3911478 | 0.77 | CACNA1B (0.44) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL8819851 | 0.77 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476759-B2 | e.g. 4-Amino-3-(4'-cyano-1,1'-biphenyl-4-yl)-4-oxobutanoic acid; antiinflammatory , anticarcinogenic, antiasthmatic agent; autoimmune disorder; osteoarthritis, rubella, Alzheimer's, Parkinson's diseases, epilepsy, osteoporosis | GLAXO GROUP LIMITED (GB) | 2009-01-13 | — | — | US | disclosed |
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1654218-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016868-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP9, MMP24 | EPHX1 1386/4885ALDH1A1 2636/4885MAPK1 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.